🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — April 20, 2026

Across these 10 US SEC filings for Q1/9M/YE 2026 financial results, a dominant theme is explosive revenue growth in hyper-scaling small caps (e.g., Karbon-X +3,869% YoY, Laser Photonics +144% YoY) clashing with widening net losses and deepening equity deficits, signaling aggressive expansion at the cost of profitability. Period-over-period trends reveal mixed revenue performance: 5/10 companies posted YoY growth (avg +728% skewed by outliers), but 6/10 reported operating/net losses expanding YoY (avg loss magnification 200%+), with gross margins stable or improving in 4 cases (e.g., MIND Tech +100 bps to 46%). Balance sheets deteriorated in 7/10 (liabilities up avg 150%, cash depletion in 5), offset by financing inflows in growth names. Capital allocation leans toward debt/equity issuance for funding (e.g., Karbon-X $10.3M financing), with rare shareholder returns (Badger Meter dividend +18%, $38.2M buybacks). REIT NETSTREIT stands out with 24% revenue growth and acquisitions ($234M), while zero-revenue shells like Blue Chip and UbuyHoldings flash high distress. Portfolio implication: Favor selective growth bets on improving cash flows (AlphaVest +1,852% cash) amid broad small-cap risk of dilution/insolvency.

10 high priority 10 total filings
· daily

US SEC Trading Suspension Halt Orders — April 20, 2026

A wave of regulatory non-compliance notices hit 6 US-listed companies on April 14-17, 2026, primarily from Nasdaq and NYSE, signaling acute distress among small-cap and emerging growth firms with trading suspensions, delistings, and delisting risks imminent. Key themes include bankruptcy-driven delistings (QVC Group and QVC Inc.), deficient stockholders' equity (Nocera at -$(440k) vs $2.5M req.), low MVPHS (Armlogi below $5M for 30 days), low bid prices (OneMedNet < $1 for 30 days), and late 10-K filings (IT Tech), with no period-over-period financial improvements noted and all sentiments negative at materiality 9-10/10. No YoY/QoQ revenue growth, margin expansions, or positive insider activity observed across filings; instead, forward-looking plans lack assurance of compliance regain. Market implications: portfolio-level pressure on Nasdaq Capital/Global Market and NYSE American listings, equity wipeouts in bankruptcies, speculative OTC trading post-delist. Emerging growth companies (Armlogi, Nocera) overrepresented, highlighting vulnerability in low-liquidity names amid 2026 market volatility.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 20, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream, a stark dichotomy emerges: 12 filings signal acute distress via bankruptcies (Charles & Colvard, QVC Group/Inc.), delisting notices (QVC stocks/notes, Armlogi, IT Tech Packaging, Nocera, OneMedNet), compliance failures, and waivers (FMC Corp leverage covenant), while 28 highlight resilience through M&A (QXO-TopBuild $17B, USA Rare Earth-Serra Verde $2.8B/SVRE, Sila Realty-Blue Owl $2.4B), financings ($58.5M Sidus, $50M Allbirds convertible), and expansions (Centrus, US Energy). Period-over-period trends are sparse but reveal mixed pressures: Alaska Air revenue +5% YoY to $3.3B but operating loss widened 42% YoY to $279M on +17% fuel costs; Limoneira Q2 FY2026 impairment $9.3M. No broad insider selling patterns, but capital allocation shifts to debt facilities/suspensions (US Energy ELOC halt) indicate liquidity focus over returns. Forward catalysts cluster in Q3 2026 (multiple M&A closings) amid Nasdaq/NYSE compliance deadlines through Oct 2026. Portfolio implication: Distressed M&A premiums (19-25%) offer alpha in building products/REITs/rare earths, but equity wipeouts in bankruptcies demand avoidance; monitor 8 compliance cures for short-term volatility.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — April 20, 2026

Across 35 SEC filings on US executive and director changes dated April 20, 2026, the dominant theme is orderly leadership transitions, with 18 appointments/promotions (e.g., new CEOs/CFOs/boards), 14 retirements/departures/resignations, and 3 extensions, averaging neutral sentiment but tilting positive (14 positive vs 1 negative). Notable clusters include 8 CFO transitions (Magnite, Snap, Westlake, Purebase, etc.) and board refreshes at AGMs (Super Micro, Synopsys, Travelzoo) with overwhelming stockholder support (avg 92% For on directors/comp). No explicit YoY/QoQ financial declines reported, but reaffirmations of prior guidance (Magnite Q1/FY2026) and strategic renewals (enCore) signal continuity; insider alignment via option grants (Travelzoo 600k shares, Neurogene RSUs) boosts conviction. Portfolio-level: Tech sector shows high stability (90%+ AGM approvals), while energy/health sees mixed renewal themes. Implications: Bullish for stability plays, monitor successor searches for volatility; relative outperformance in firms extending tenures (Kingstone CEO to 2029).

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 20, 2026

Across 35 SEC filings on USA Board Room Changes from April 20, 2026, a surge in C-suite and board transitions dominates, with 18 appointments/promotions (e.g., CEOs, CFOs, directors) signaling strategic refreshes amid neutral-to-positive sentiment (avg materiality 6.5/10), contrasted by 12 resignations/retirements and 3 terminations, often without disagreements. Period-over-period trends inferred from contexts show stable-to-improving operational metrics in 70% of cases (e.g., no performance declines noted in Revium Rx), with forward-looking commitments to cost management (enCore), growth roadmaps (Kingstone targeting $500M premiums by 2029), and continuity via advisors/internal promotions. Portfolio-level patterns reveal finance/tech sectors leading changes (14/35 filings), with experienced external hires boosting conviction (e.g., Baksht at Westlake/Chemical Partners). Insider activity via equity grants (e.g., Travelzoo CEO 600k options vesting June 2026) indicates alignment, though opposition to comp (Travelzoo 30% against CEO grant) flags scrutiny. Critical implications: opportunities in turnaround stories (enCore renewal program), risks from interim leadership (Fermi Office of CEO), and catalysts like enCore's April 23 call. Overall, bullish on hires with deep expertise (e.g., Neurogene CCO with 20+ yrs rare disease launches), bearish on abrupt exits (Purebase CFO termination).

35 high priority 35 total filings
· daily

US Merger & Acquisition SEC Filings — April 20, 2026

The six filings highlight a surge in SPAC-related M&A activity and corporate restructurings within the USA M&A & Takeover stream, with 4/6 involving SPACs (mergers, extensions, financing, compliance). A standout $280M enterprise value de-SPAC with Tigerless Health and a biotech spin-off unlocking value via AnaptysBio (now >95% EBIT margin, $140-145M net cash) and First Tracks ($180M cash, 2-year runway) dominate positive developments. No period-over-period declines or flat operational metrics reported across filings where specified (e.g., First Tracks), contrasting with YHN's Nasdaq non-compliance. Forward-looking catalysts cluster in H2 2026, including deal closes and compliance deadlines. Portfolio-level trends show SPAC persistence amid liquidity support, with positive sentiment in 5/6 filings implying near-term listing opportunities and value separation, though delisting risks loom for underperformers. Overall, actionable alpha from spin-off pure-plays and SPAC resolutions outweighs isolated distress signals.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 20, 2026

Overnight SEC filings reveal a surge in M&A activity, headlined by QXO's $17B acquisition of TopBuild (19.8% premium, Q3 2026 close) creating a $18B revenue building products giant, USA Rare Earth's $2.8B Serra Verde deal for rare earth dominance (Q3 2026), and Calavo-Mission merger advancing post-HSR clearance (Q2 2026 target). Period-over-period trends show mixed financials: revenue declines in miners/tech like SOLAI (-30% YoY to $23M), DAQO (-35% to $665M), Blue Chip (0 rev, net loss -$17.8M 9M'26 vs -$1.5M prior), offset by growth in Tuniu (+12.5% YoY), Cleveland-Cliffs (+6% YoY rev to $4.9B), Investar (EPS $0.77 Q1'26 +51% QoQ), SmartFinancial (stable $0.81 EPS). Biotech/clinical positives (Prelude, Monopar, Perspective) and SPAC deals (Piermont-Tigerless, ClimateRock extension) add catalysts, while banks show NIM expansion (Investar +39bps QoQ to 3.59%, Smart +10bps to 3.48%) but rising NPLs. Portfolio-level: 5/10 financials mixed with loan/deposit growth but credit deterioration; energy derivatives losses (Infinity $65M Q1); capital allocation favors buybacks (News Corp $1B program). Implications: M&A drives consolidation in building/rare earths, monitor Q3 closings and proxy votes for dilution risks.

21 high priority 29 medium 50 total filings
· daily

VA Healthcare & Services Contracts — April 18, 2026

The VA Healthcare & Services Contracts stream reflects a single $928,900,085 obligation to TriWest Healthcare Alliance Corp from the Department of Veterans Affairs, with a 0/1 defense-related split indicating fully civilian exposure. This high-materiality firm fixed price delivery order for health and medical insurance carriers (NAICS 524114, PSC G007) under full and open competition carries a neutral highest-conviction signal (strength 5/10) due to its anomalous one-month performance period in March 2026 and no funds outlayed despite total obligation matching base + options. The dominant agency theme is Department of Veterans Affairs health insurance programs via delivery order, lacking multi-year visibility. Key risk is the award date (2026-04-16) post-dating performance end (2026-03-31), introducing execution uncertainty and high pricing risk.

1 total filings
· daily

New Federal Contractors — April 18, 2026

These 6 new federal contracts total $4,180,930,218 in obligations, entirely civilian with 0 defense-related awards, led by health and human services themes from HHS ($2.78B to MAXIMUS FEDERAL SERVICES, INC.) and VA ($928.9M to TRIWEST HEALTHCARE ALLIANCE CORP). Dominant agencies include HHS, VA, GSA, EPA, and NASA, signaling civilian health insurance and engineering services momentum. Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), supporting DTRA IMAX DA with low pricing risk. Key risk is data anomalies including $0 outlayed for TriWest VA contract, negative -$530K outlayed for CACI, and post-performance award dates, warranting funds progress monitoring.

6 total filings
· daily

Significant Contract Modifications ($10M+) — April 18, 2026

These six significant contract modifications totaling $4,180,930,218 in obligations are entirely civilian (0/6 defense-related), dominated by health and human services themes from HHS ($2.78B to MAXIMUS FEDERAL SERVICES, INC.) and VA ($928.9M to TRIWEST HEALTHCARE ALLIANCE CORP). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering services delivery order (strength 8/10), supporting DTRA IMAX DA with low pricing risk under cost-plus-award-fee structure. Lockheed Martin secures two minor NASA space R&D contracts totaling $6M, but with low materiality. Key risk is data anomalies including zero outlays on TriWest's $928.9M VA award, negative outlays (-$530K) on CACI, and future-dated performance periods conflicting with April 2026 award dates.

6 total filings
· daily

Contract Deobligations Alert — April 18, 2026

$4,180,930,218 in contract deobligations across 6 civilian awards (0/6 defense-related) highlight volatility in HHS, VA, GSA, EPA, and NASA spending, with average signal strength of 4.7/10. Dominant agency theme is health services via HHS ($2.78B to MAXIMUS FEDERAL SERVICES, INC.) and VA ($928.9M to TRIWEST HEALTHCARE ALLIANCE CORP.), alongside GSA engineering ($399.6M to CACI NSS, LLC). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M cost-plus-award-fee delivery order from GSA, signaling low pricing risk and potential extension to 2026. Balanced view shows neutral execution risks from zero or negative outlays in top awards. Key watch item: TriWest's $928.9M award dated post-performance period (2026-04-16 after March 2026 end), risking non-execution.

6 total filings
· daily

Contract Option Exercises — April 18, 2026

These six contract option exercises total $4,180,930,218 in obligations, with 0/6 defense-related and fully civilian agency focus across HHS, VA, GSA, EPA, and NASA. Dominant themes include health and medical insurance services (HHS MAXIMUS FEDERAL SERVICES, INC. at $2.78B and VA TRIWEST HEALTHCARE ALLIANCE CORP at $928.9M) and engineering/R&D support. Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), signaling durable cost-plus award fee revenue through potential 2026 extension. Key risk is data anomalies including TriWest's $0 outlayed with future performance dates (March 2026) and CACI's negative -$530K outlayed, warranting close funds progress monitoring.

6 total filings
· daily

Federal Professional Services Contracts — April 18, 2026

Across one federal professional services contract in the April 18, 2026 period, total obligations reached $399,565,757, with a 0/1 defense/civilian split entirely in the civilian sector via GSA Federal Acquisition Service's FEDSIM office. The dominant theme is engineering services (NAICS 541330) supporting DTRA IMAX DA, highlighted by CACI NSS, LLC's $399,565,757 delivery order awarded in 2021 under full and open competition. Highest-conviction signal is bullish for CACI INTERNATIONAL INC, signaling ~$80M annual revenue potential over a 5-year period if options extend to June 29, 2026. Key risk is execution uncertainty from negative total outlayed of -$530,151 and current end date of June 29, 2023, warranting watch on option exercises.

1 total filings
· daily

All HHS Contracts — April 18, 2026

HHS drove 100% of the $2,779,736,793 in total obligations during April 18-18, 2026, with a 0/1 defense-related split confirming purely civilian exposure. MAXIMUS FEDERAL SERVICES, INC. captured the entirety of this value via a single $2.78B award, marking the dominant agency and contractor theme in HHS services. The highest-conviction signal is bullish for MAXIMUS at 7/10 strength and 8/10 materiality, underscoring potential revenue tailwinds in government services. A key watch item is the unknown competition signal, which could expose the award to protests or re-competes given the contract's scale.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 18, 2026

Three civilian mega contracts totaling $4,108,202,635 were awarded across HHS, VA, and GSA, with zero defense-related obligations, highlighting robust demand in health administration, insurance, and engineering services. Dominant themes center on VA and HHS health/insurance programs alongside GSA engineering support, led by MAXIMUS FEDERAL SERVICES, INC.'s $2.78B HHS award as the highest materiality bullish signal at 8/10. CACI NSS, LLC's $399.6M GSA delivery order adds a high-conviction bullish signal (8/10 strength) for engineering services with potential extension to 2026. TRIWEST HEALTHCARE ALLIANCE CORP's $928.9M VA order remains neutral due to data anomalies including zero funds outlayed and post-performance award date. Key watch item: monitor TriWest funds outlay progress and CACI option exercises beyond June 29, 2023 amid negative outlays.

3 total filings
· daily

High-Value Federal Grants ($5M+) — April 18, 2026

High-value federal grants totaling $4,174,924,202 were awarded across four civilian contracts from April 18, 2026, with zero defense-related activity, highlighting pure civilian agency exposure in health services, engineering, and environmental remediation. Dominant themes center on Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) health/insurance programs, comprising over 90% of value via MAXIMUS FEDERAL SERVICES, INC. ($2.78B) and TRIWEST HEALTHCARE ALLIANCE CORP. ($929M). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), supporting potential revenue of $80M/year through 2026. Key risk is execution anomalies, including TRIWEST's $0 outlay and post-performance award date, plus CACI's negative -$530K outlayed.

4 total filings
· daily

General Federal Contracts — April 18, 2026

These four civilian contracts total $4,174,924,202 in obligations with 0/4 defense-related, highlighting HHS and VA dominance in health services alongside GSA engineering and EPA remediation. MAXIMUS FEDERAL SERVICES, INC. leads with a massive $2.78B HHS award, while CACI NSS, LLC secured a bullish $399.6M GSA engineering delivery order. Highest-conviction signal is CACI's Cost Plus Award Fee structure with low pricing risk and potential extension to 2026. Key risk is data anomalies including TriWest's $928.9M VA award with future performance dates (March 2026) post-award (April 2026) and $0 outlay, plus CACI's negative -$530K outlay.

4 total filings
· daily

All NASA Contracts — April 18, 2026

NASA awarded $6,006,015 in total obligations across two contracts to Lockheed Martin Corporation from NASA Glenn Research Center, representing a 100% civilian split with 0/2 defense-related awards. The dominant theme is basic space R&D services (PSC AR11, NAICS 541715) under cost-plus-fixed-fee structures, both non-competed with no set-asides. Highest-conviction signal is neutral (avg strength 2/10, materiality 1/10), reflecting minor revenue additions for Lockheed Martin amid ongoing NASA basic research funding. Both contracts show significant outlays ($3,210,919 and $2,264,952 respectively) with options unexercised, signaling low execution risk but limited upside. Key watch item: monitor option exercises to reach $3,871,841 and $2,671,620 ceilings by performance end date of 2026-06-30.

2 total filings
· daily

Biotech Small-Cap Approvals — April 17, 2026

The FDA recorded 4 'Other' (fallback) approvals from April 13-15, 2026, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, all with neutral signals. These involve small-molecule generic-style entries by MSN (GLYCEROL PHENYLBUTYRATE), APOTEX (CANAGLIFLOZIN), MICRO LABS (HYDROCHLOROTHIAZIDE), and NOVITIUM PHARMA (PIMOZIDE), spanning disparate therapeutic areas with no dominant theme. Highest-conviction signal is NOVITIUM PHARMA's PIMOZIDE approval (neutral, 5/10 strength and materiality), implying routine market entry with commercial details NOT_DISCLOSED. Key risk/watch item: Potential revenue pressure on originators from these entrants, balanced by neutral entrant upside absent peak sales or exclusivity data.

4 total filings
· daily

Orphan Drug Approvals — April 17, 2026

This period featured 1 FDA orphan drug approval: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other (fallback approval). No dominant therapeutic area theme emerged from the single approval. The highest-conviction bullish signal is Travere's Sparsentan (Filspari) label expansion, signaling portfolio strengthening in the orphan space with medium commercial materiality. Key risk/watch item is limited visibility into peak sales, exclusivity, pricing, and market position due to NOT_DISCLOSED data, warranting post-approval uptake monitoring.

1 total filings